Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 258 Carcinoma, Non-Small-Cell Lung 222 Carcinoma, Renal Cell 141 Neoplasm Metastasis 96 Neoplasms 92 Carcinoma, Hepatocellular 84 Squamous Cell Carcinoma of Head and Neck 83 Colorectal Neoplasms 78 Lung Neoplasms 71 Stomach Neoplasms 55 Pancreatic Neoplasms 55 Carcinoma, Transitional Cell 48 Hodgkin Disease 45 Urinary Bladder Neoplasms 42 Breast Neoplasms 40 Ovarian Neoplasms 37 Head and Neck Neoplasms 37 Triple Negative Breast Neoplasms 33 Small Cell Lung Carcinoma 33 Sarcoma 32 Glioblastoma 32 Brain Neoplasms 32 Prostatic Neoplasms 31 Recurrence 28 Kidney Neoplasms 27 Multiple Myeloma 25 Uveal Melanoma 23 Esophageal Neoplasms 23 Skin Neoplasms 22 Lymphoma 22

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡